Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNIB0600A versus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer
2012-005776-34Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lifastuzumab vedotin, doxorubicin in ovarian cancer, sponsored by Genentech. Started Oct 2013; status: completed.
02
Drugs
lifastuzumab vedotindoxorubicin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2012-005776-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005776-34.